Can a patient with a history of type 2 diabetes or obesity develop loose stools or diarrhea after discontinuing Glucagon-like peptide-1 (GLP-1) medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Patients Develop Loose Stools or Diarrhea After Discontinuing GLP-1 Medications?

No, patients do not typically develop loose stools or diarrhea after discontinuing GLP-1 receptor agonists; in fact, the opposite is true—GLP-1 medications cause diarrhea during active treatment, and discontinuation should lead to resolution of these gastrointestinal symptoms.

Understanding GLP-1 Effects on the GI Tract

GLP-1 receptor agonists work by delaying gastric emptying, reducing gastric acid secretion, and increasing gastric volumes, with their primary effects concentrated in the upper gastrointestinal tract 1. These medications do not cause fat malabsorption, which would be the typical mechanism for loose or floating stools 1.

Active Treatment Side Effects

During active GLP-1 therapy, gastrointestinal adverse effects are common and well-documented:

  • Diarrhea is a recognized side effect while ON the medication, occurring alongside nausea, vomiting, and constipation 2, 3
  • Gastrointestinal disturbances are frequent during GLP-1 use, with most adverse events occurring within the first month of therapy 1
  • These side effects may improve with continued use due to tachyphylaxis (the body adapting to the medication over time) 1, 4
  • The effects are dose-dependent, with short-acting formulations causing more GI symptoms than long-acting preparations 1

What Happens After Discontinuation

When GLP-1 medications are stopped, the physiological effects reverse:

  • Gastric emptying gradually returns to normal as the medication's effect on delaying gastric motility wears off 2, 4
  • The delayed gastric emptying effect persists for some time after discontinuation, with studies showing retained gastric contents even 4-6 days after stopping 5
  • There is a decreasing prevalence of gastric retention with each additional day of drug discontinuation 2

Clinical Implications

If a patient develops diarrhea AFTER stopping GLP-1 therapy, look for alternative causes:

  • Assess for concurrent medications affecting gastrointestinal function 1
  • Evaluate dietary changes, particularly excessive fat intake 1
  • Consider other conditions affecting fat absorption 1
  • Review for bile acid diarrhea, which interestingly may have been suppressed by the GLP-1 medication itself 6

Important Caveat About Bile Acid Diarrhea

One notable exception exists: GLP-1 receptor agonists (particularly liraglutide) have been shown to effectively treat bile acid diarrhea by reducing bowel movements 6. In patients with underlying bile acid diarrhea, discontinuing GLP-1 therapy could unmask or worsen pre-existing diarrhea that was being therapeutically suppressed by the medication 6.

Common Pitfalls to Avoid

  • Do not attribute new-onset diarrhea after GLP-1 discontinuation to the medication withdrawal itself—this is not a recognized withdrawal effect 2, 1
  • Remember that constipation (not diarrhea) is actually more commonly associated with semaglutide use, with a risk ratio of 6.17 during active treatment 1
  • Consider that the patient may have had underlying bile acid diarrhea that was being masked by the GLP-1 medication's therapeutic effect 6

References

Guideline

GLP-1 Receptor Agonists and Gastrointestinal Effects

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Gastric Overload in Patients Taking Semaglutide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.